Skip to content
2000
Volume 21, Issue 8
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Glioblastoma multiforme (GBM), as the most lethal brain tumor, continues to be incurable. Considering the high mortality rate of GBM, it is crucial to develop new treatment approaches. Conventional therapies, including maximal surgical resection, radiation therapy, and chemotherapy (typically temozolomide), have not led to significant changes in the survival rates of GBM patients. However, emerging modalities, such as the use of tyrosine kinase inhibitors, mTOR inhibitors, NF-ΚB modulators, nitrosoureas, and immunotherapeutic agents have shown promising in improving GBM outcomes. In this context, we reviewed the current status of GBM treatment, the efficacy of existing standard therapies in improving disease outcomes, and future therapeutic directions.

Loading

Article metrics loading...

/content/journals/cdm/10.2174/1389200221666200714101038
2020-07-01
2025-05-21
Loading full text...

Full text loading...

/content/journals/cdm/10.2174/1389200221666200714101038
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test